339 completed, 132 unknown, 93 recruiting, 81 terminated. 784 Phase 2, 122 Phase 1, 34 Phase 3.
Follow Rectal Neoplasms: new trials by email Literature Review of Rectal Neoplasms trials Research Report on Rectal Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET/MRI in Rectal Cancer Total Neo-adjuvant Therapy, 18FDG-PET/MRI scan - Rectal Cancer | Phase 2 | Not yet recruiting | AHS Cancer Control Alberta | 40 | 2027-05-01 | 2026-10-28 |
| Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC) Cemiplimab - Colon and Rectal Cancer | Phase 2 | Recruiting | Columbia University | 20 | 2027-01-01 | 2026-11-04 |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| A Study of Retifanlimab After Chemoradiation in People With Anal Cancer Retifanlimab - Anal Squamous Cell Carcinoma, Anal Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 25 | 2026-11-04 | 2026-11-10 |
| Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates High Rare Dose Rectal Brachytherapy Boost - Rectal Adenocarcinoma, Rectal Cancer | Phase 2 | Recruiting | University of Colorado, Denver | 44 | 2026-11-01 | 2026-09-02 |
| A Prospective, Biomarker-Stratified Phase 2 Study: β-Hydroxybutyrate as a Predictive Biomarker for Short-Course Radiotherapy Followed by Chemotherapy Plus PD-1 Inhibitor Versus Chemotherapy Alone in Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Not yet recruiting | Tao Zhang | 144 | 2026-11-01 | 2026-10-06 |
| Adaptive Radiotherapy for Safe Hypofractionation Adaptive Hypofractionated Radiotherapy, Standard-of-care Radiotherapy - Cancer, Endometrial Cancer | Phase 2 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 264 | 2026-11-01 | 2026-10-29 |
| Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer DCSZ11, Radiation, Capecitabine - Rectal Cancer | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 30 | 2026-11-01 | 2026-10-28 |
| Radiotherapy Plus Putelimab and Vibostolimab for Advanced Anal Squamous Cell Carcinoma putelimab combined with vibostolimab - Anal Cancer | Phase 2 | Not yet recruiting | Fudan University | 33 | 2026-10-31 | 2026-11-13 |
| ctDNA-Informed Management of Early-Stage Rectal Cancer Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) - Rectal Adenocarcinoma, Rectal Cancer | Phase 2 | Not yet recruiting | University of California, Davis | 200 | 2026-10-01 | 2026-08-05 |
| 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer 16-Hour Fasting, Serplulimab + chemotherapy - pMMR/MSS, Locally Advanced Rectal Carcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 51 | 2026-10-01 | 2026-09-08 |
| A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer Fam-Trastuzumab Deruxtecan-Nxki - Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 27 | 2026-10-01 | 2026-10-01 |
| Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer Lenvatinib, Pembrolizumab - Anal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 17 | 2026-09-30 | 2026-07-02 |
| mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer FOLFOXIRI + Bevacizumab - Phase 2 Study | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 119 | 2026-09-30 | 2026-09-14 |
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial Drug：sintilimab, Drug：Capecitabine, Drug：Suvemcitug - Rectal Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 18 | 2026-09-01 | 2026-08-19 |
| Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer mFOLFOX6, Suvemcitug, Enlonstobart - Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 52 | 2026-08-28 | 2026-09-09 |
| Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma Hypofractionated Radiation Therapy - Anal Cancer | Phase 2 | Enrolling by invitation | University of Vermont Medical Center | 24 | 2026-08-26 | 2026-09-15 |
| Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial Arginine-Deprived Diet, Short-Course Radiotherapy (SCRT), CAPOX + PD-1 Inhibitor - Rectal Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | West China Hospital | 140 | 2026-08-14 | 2026-08-10 |
| RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer Botensilimab, Balstilimab - Early Rectal Cancer, Stage I Rectal Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 16 | 2026-08-10 | 2026-11-03 |
Showing 20 of 784. Sign in to see all of them.
Colonic Neoplasms (314) · Colorectal Neoplasms (274) · Anus Neoplasms (81) · Neoplasm Metastasis (60) · Neoplasms (33) · Uterine Cervical Neoplasms (32) · Pancreatic Neoplasms (29) · Stomach Neoplasms (21) · Breast Neoplasms (19) · Prostatic Neoplasms (17) · Endometrial Neoplasms (15) · Esophageal Neoplasms (15) · Adenocarcinoma (14) · Lung Neoplasms (14)
Digestive System Diseases (782) · Rectal Diseases (782) · Digestive System Neoplasms (781) · Gastrointestinal Diseases (780) · Intestinal Diseases (780) · Neoplasms by Site (780) · Intestinal Neoplasms (778) · Gastrointestinal Neoplasms (771) · Neoplasms (751) · Colorectal Neoplasms (510) · Colonic Diseases (362) · Pathological Conditions, Signs and Symptoms (100) · Pathologic Processes (89) · Anus Diseases (81)
Oxaliplatin (173) · Fluorouracil (172) · Capecitabine (148) · Leucovorin (118) · Irinotecan (98) · Radiotherapy (89) · Bevacizumab (73) · Cetuximab (57) · Drug Therapy (31) · Folfox protocol (30) · Radiation (30) · Surgical Procedures, Operative (28) · Panitumumab (22) · Neoadjuvant Therapy (20) · XELOX (19)
National Cancer Institute (NCI) (52) · Memorial Sloan Kettering Cancer Center (24) · M.D. Anderson Cancer Center (17) · Alliance for Clinical Trials in Oncology (16) · Sun Yat-sen University (16) · Fudan University (13) · Sixth Affiliated Hospital, Sun Yat-sen University (12) · Amgen (10) · Roswell Park Cancer Institute (10) · City of Hope Medical Center (9) · GERCOR - Multidisciplinary Oncology Cooperative Group (9) · SWOG Cancer Research Network (9) · UNICANCER (8) · Chinese Academy of Medical Sciences (7) · Eastern Cooperative Oncology Group (7)
United States (342) · China (131) · France (58) · Canada (43) · Spain (28) · Germany (26) · United Kingdom (26) · South Korea (25) · Netherlands (22) · Italy (21) · Belgium (15) · Japan (13) · Switzerland (13) · Australia (12) · Brazil (11)
Leonard B. Saltz, MD (6) · Hedy L. Kindler, MD (5) · Howard S. Hochster, MD (5) · Marwan Fakih, MD (5) · Robert P. Whitehead, MD (4) · Alexander de Vries, MD (3) · Andrea Cercek, MD (3) · Cathy Eng (3) · Dominique Elias, MD (3) · Heinz-Josef Lenz, MD (3) · Joel Palefsky, MD (3) · John H Strickler (3)
PMID 15496622, PMID 26187751, PMID 27602924, PMID 28223062, PMID 14616164, PMID 15927411, PMID 16099600, PMID 17042060, PMID 17401014, PMID 17976611, PMID 20065174, PMID 20106720, PMID 21494121, PMID 21550216, PMID 22070868, PMID 23578724, PMID 26049686, PMID 26808342, PMID 27480145, PMID 28594719, PMID 30192320, PMID 30279338, PMID 32251400, PMID 32530769, PMID 33538338, PMID 35660797, PMID 41379261, PMID 41544350, PMID 11316150, PMID 11919232, PMID 12448660, PMID 12835883, PMID 12860947, PMID 14673042, PMID 15629599, PMID 15641483, PMID 15668285, PMID 15690650, PMID 15709193, PMID 15712779, PMID 15868260, PMID 15895230, PMID 16009952, PMID 16061869, PMID 16062074, PMID 16098249, PMID 16110021, PMID 16230673, PMID 16361624, PMID 16446336
P30CA033572 (8), U10CA031946 (6), U10CA032102 (6), P30CA015083 (5), P30CA016672 (5), U10CA180820 (5), 2025 (3), P30CA015704 (3), P30CA016056 (3), P30CA016087 (3), U01CA121947 (3), U10CA180821 (3), 2008 (2), 2014 (2), 2015 (2)